Growth target now set at 10-11% for year-end. Forecasts now stand at 6-8% for 2024. The analyst confirms his neutral recommendation on the stock, with an unchanged target of E44, which represents a potential upside of 24%.

'Confirmation that Medidata will return to growth in the second half and that CFO increased year-on-year in the first half were positive elements, but the 10-11% growth plans for the fourth quarter will make some nervous' says UBS.

DS has pre-announced sales 40 million euros below the mid-point, and reduced full-year forecasts by 120 million euros below the mid-point, due to a decline in contracts, mainly in the A&D sector', points out the analyst firm.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.